Alexis Battle is an Associate Professor at Johns Hopkins University with appointments in Biomedical Engineering , Computer Science , and Genetic Medicine (secondary). She directs the Malone Center for Engineering in Healthcare and serves as Deputy Director of the Data Science and AI Institute . Educated at Stanford University (PhD in Computer Science, 2013), Battle transitioned to academia after leadership roles at Google. Research Focus: Battle’s work bridges genomics and machine learning , emphasizing the impact of genetic variation on human health. Her lab develops tools like Watershed to predict functional effects of rare variants, aiming to enhance rare disease diagnosis. Key themes include non-coding DNA analysis , personalized genomics , and systems biology , with applications in cardiovascular disease and neurodegenerative disorders . Publications & Awards: Over 60 peer-reviewed articles in journals like Nature , Science , and Genome Biology , with recent emphasis on single-cell transcriptomics , multiomics integration , and telomere biology . Recipient of the President’s Frontier Award (2022), Microsoft Investigator Fellowship (2019), and Searle Scholar (2016). Scientific Awards: 2022 President’s Frontier Award 2019 Microsoft Investigator Fellowship 2019 Johns Hopkins Discovery Award 2017 Johns Hopkins Catalyst Award 2016 Searle Scholar Advising & Funding: Mentors 11 PhD students, 3 undergraduates, and postdoctoral fellows. Her research is funded by NIH, Searle Scholars, and institutional grants. The Battle Lab collaborates on projects like the GTEx Consortium , focusing on gene regulation and clinical genomics .
Allison Ross Eckard, MD is Professor in the Departments of Pediatrics and Medicine at the Medical University of South Carolina (MUSC) College of Medicine, serving as Division Chief for Pediatric Infectious Diseases and Director of MUSC's Ryan White Pediatric HIV Clinic and HIV Transition Clinic. She maintains an adjunct faculty position at Emory University and holds board certification in Pediatrics and Pediatric Infectious Diseases. Her primary research focuses on metabolic, cardiovascular, and nutritional complications of chronic HIV and antiretroviral therapy across age groups, with emphasis on inflammation's role in comorbidities like cardiovascular disease and bone disorders. Current investigations include NIH R01-funded research on interventions for weight gain and abdominal fat in HIV, vitamin D supplementation, and statin therapy. She has published nearly 60 peer-reviewed papers on HIV pathogenesis and treatment optimization. Dr. Eckard co-chairs the DHHS panel for Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children and serves on the DHHS panel for Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV . Her clinical work specializes in comprehensive HIV care for children through young adults, with particular focus on adolescent/young adult transition issues and global health initiatives through Lespwa Timoun in Haiti. Recent efforts include developing COVID-19 treatment guidelines for children and school safety protocols. HIV Specialist certification (American Academy of HIV Medicine) Fellow, Infectious Diseases Society of America Fellow, Pediatric Infectious Diseases Society Fellow, HIV Medical Association Member, HIV Medical Association's 'Ending the HIV Epidemic' working group She leads MUSC's HIV education initiatives and serves as inpatient consultant for pediatric infectious diseases, with advanced training in tropical medicine. Her NIH-funded research examines targeted interventions to minimize comorbidity development in HIV, while her clinical leadership spans the Ryan White HIV program, transition clinics, and global health partnerships.
Dr. Pascal Syren is a **Researcher** and **Resident** at Heidelberg University Hospital (UKHD), affiliated with the **Department of Cardiology, Angiology, and Pulmonology** and the **Heidelberg Center for Cardiac Arrhythmias**. His academic role includes contributing to the **Group of Molecular and Translational Cardiac Electrophysiology**, focusing on epigenetic and molecular mechanisms underlying cardiac arrhythmias and heart failure. He holds a PhD from Heidelberg University (2021) on histone deacetylases' influence in cardiac electrophysiology. **Research Interests**: Cardiac electrophysiology, epigenetic regulation (HDACs), ventricular and atrial arrhythmias, echocardiography, and translational cardiology. His work spans basic science to clinical applications, emphasizing ion channel remodeling and therapeutic targets for heart rhythm disorders. **Awards**: Recipient of the **Ernst & Berta Grimmke Foundation Research Grant (2023–2024)** and **Otto-Hess Scholarship (2017–2018)** from the German Cardiac Society. His research bridges molecular mechanisms with clinical cardiology, with contributions to understanding HDAC2's role in action potential dynamics. **Publications**: Over 8 peer-reviewed articles (2016–2025) in journals like *Basic Research in Cardiology* and *Cells*, focusing on histone deacetylase pathways, atrial fibrillation, and ventricular arrhythmia models. Recent work explores neonatal cardiomyocyte electrophysiology and TREK-1 potassium channels in heart failure. **Affiliations**: Active member of the **German Cardiac Society (DGK)** and **European Society of Cardiology (ESC)**, contributing to interdisciplinary cardiac arrhythmia research at Heidelberg's medical faculty.
Andre Levchenko is the John C. Malone Professor of Biomedical Engineering at Yale University, with secondary appointments in the Department of Neurosurgery and affiliations with the Cancer Signaling Networks, Immunology, and the Yale Program in Neurodevelopment and Regeneration. His research focuses on systems biology, signal transduction, and cell-cell communication, utilizing microfluidics and computational modeling to study cancer progression, stem cell behavior, and neurological disorders. PhD, Columbia University MEng, Moscow Institute of Physics and Technology Levchenko's work explores how cells process dynamic signals to make critical decisions, particularly in glioblastoma migration, organoid development, and cardiovascular tissue engineering. His lab develops innovative microfluidic platforms and mathematical models to dissect multicellular communication and signaling networks. Recent publications highlight his contributions to understanding YAP-driven cancer invasion , NOTCH signaling in angiogenesis , and metabolic regulation of hypoxia responses . He has pioneered methods for organoid modeling and single-cell analysis , advancing precision in biological signaling studies. Scientific Awards : Computational Molecular Biology Post-Doctoral Fellowship (Burroughs Wellcome Fund) National Academies Keck Futures Conference Invitee Distinguished Guest Lecturer, University of Virginia American Asthma Foundation Early Excellence Award Fellow, American Institute for Medical and Biological Engineering Levchenko leads the Levchenko Lab at the Yale Systems Biology Institute, collaborating with institutions like Mayo Clinic and Yale Cancer Center. His research has received recognition in Faculty of 1000 and multiple journal highlights.
David H. Sherman is the Hans W. Vahlteich Professor of Medicinal Chemistry at the University of Michigan, holding joint appointments in the College of Pharmacy (Department of Medicinal Chemistry), Medical School (Microbiology & Immunology), and College of Literature, Science, and the Arts (Chemistry). He leads the Sherman Lab at the Life Sciences Institute and co-founded the Natural Products Discovery Core. His research focuses on natural product discovery, biosynthetic pathways, and drug development for infectious diseases, cancer, and neurological disorders. Education: PhD in Synthetic Organic Chemistry from Columbia University (1981), BA in Chemistry from UC Santa Cruz (1978). Postdoctoral research at MIT (1984). Research interests include microbial secondary metabolites, enzymatic catalysis (e.g., C-H functionalization, polyketide assembly), and high-throughput drug screening. He pioneered a microbial natural product library with over 50,000 samples. Current projects emphasize developing macrolide antibiotics and advancing compounds toward clinical trials through the Natural Products Biosciences Initiative. Collaborations span global institutions, with a focus on biodiversity conservation and capacity-building in low-income nations. He has mentored 67 PhD students, 60 postdocs, and 85+ undergraduates, fostering interdisciplinary training in chemical biology and microbial biochemistry. Labs/Teams: Sherman Lab (Life Sciences Institute), Center Member at Samuel and Jean Frankel Cardiovascular Center, Center for Computational Medicine and Bioinformatics, Rogel Cancer Center.
Clifton R. Haider, Ph.D., is a Professor of Biomedical Engineering at Mayo Clinic, holding primary appointments as a Consultant in the Department of Physiology & Biomedical Engineering and the Department of Pediatric and Adolescent Medicine. His research focuses on accelerating medical device development through a discovery platform integrating mathematical modeling, algorithmic design, and physiological sensor validation. This platform aims to identify predictive biomarkers for conditions like cardiovascular collapse, sleep disorders, and neurodegenerative diseases. Dr. Haider’s work emphasizes noninvasive, autonomous monitoring and real-time predictive algorithms, with a particular focus on pediatric care. Education: PhD, Physiology & Biomedical Engineering, Mayo Graduate School, Mayo Clinic College of Medicine Predoctoral Studies in Biomedical Engineering and Physiology, Mayo Graduate School BSc (Hons), Biomedical Engineering, University of Iowa Research Interests: Dr. Haider’s work bridges engineering and clinical practice, targeting unmet needs in pediatric and adult healthcare. His discovery platform combines statistical modeling, sensor design, and validation to streamline medical device prototyping. Key focus areas include: Accelerated medical device design Quantitative predictive biomarkers Remote pediatric monitoring Real-time algorithm development This platform seeks to predict treatment responses and identify patients requiring advanced care, enhancing clinical decision-making. Awards: Office of Naval Research Young Investigator Program (2014–present) Grants & Labs: His research is supported by interdisciplinary collaborations at Mayo Clinic, leveraging laboratory facilities for sensor validation and algorithm testing. While specific grant details are not listed, his work aligns with Mayo’s emphasis on translational biomedical engineering.
Karin Allor Pfeiffer is a Professor in the Department of Kinesiology at Michigan State University (MSU) and Director of the Institute for the Study of Youth Sports. She holds additional membership in the Center for Physical Activity and Health. With a Ph.D. from MSU, her research focuses on physical activity measurement methodologies and population health interventions, particularly among children and adolescents. Her work addresses obesity prevention, environmental design impacts on activity levels, and sociocultural factors influencing youth sport participation. Education: Ph.D. in Kinesiology from Michigan State University Her research interests emphasize: - Quantitative methods for physical activity assessment - Schoolyard redesign strategies and their health impacts - Cardiometabolic risk factors in pediatric populations - Longitudinal tracking of physical fitness and health outcomes Recent work explores accelerometer fragmentation metrics, GPS-linked activity tracking, and disparities in sedentary behavior across demographic groups. She has pioneered interdisciplinary approaches integrating spatial analysis, wearable technology, and policy evaluation. Key contributions include developing the Observational System for Recording Physical Activity in Children and advancing consensus methods for accelerometer data interpretation. Her studies frequently highlight socioeconomic and environmental determinants of health behaviors. Dr. Pfeiffer collaborates with public health agencies and urban planners to translate research into actionable policies. Her lab focuses on scalable interventions for underserved communities, leveraging community-engaged methods to address greenspace accessibility and safety concerns.
Susan A. Murphy is the Mallinckrodt Professor of Statistics and of Computer Science at Harvard University, with affiliations to the Kempner Institute. She leads the Statistical Reinforcement Learning Lab, focusing on developing algorithms to inform sequential decision-making in health, particularly for Just-in-Time Adaptive Interventions (JITAIs) and micro-randomized trials (MRTs). Her work is funded by NIH institutes, including NIDA, NHLBI, and NIBIB. Dr. Murphy has been awarded a MacArthur Fellowship (2013) and is a member of the National Academy of Medicine (2014) and the National Academy of Sciences (2016). Her research integrates statistical methods with computer science techniques to optimize mobile health interventions. She collaborates with d3Lab and mDOT on projects like HeartSteps and Sense2Stop, evaluating real-time treatment policies. Notable contributions include advancing MRT designs, sample size calculations, and reinforcement learning algorithms for personalized healthcare. Dr. Murphy advises a large team of postdocs, graduate students, and undergraduates, many of whom hold academic and industry roles globally. She emphasizes engagement in digital interventions, balancing personalization with ethical considerations. Her lab’s work spans algorithm development, clinical trial design, and causal inference, aiming to improve health outcomes through adaptive interventions.
Wing Lam is an Associate Research Scientist in the Department of Pharmacology at the Yale School of Medicine. He holds a BSc in Molecular Biology and a PhD in Biochemical Pharmacology from City University of Hong Kong, followed by postdoctoral training at Yale. His research focuses on developing traditional Chinese medicine (TCM) formulations as adjuvants for cancer therapy, notably YIV-906, which enhances chemotherapy efficacy and mitigates intestinal toxicity. Lam also pioneered the STAR database for herbal drug discovery and the Mechanism-Based Quality Control (MBQC) platform for botanical drug standardization. Education: BSc (Hons) Molecular Biology, City University of Hong Kong, 1995 PhD Biochemical Pharmacology, City University of Hong Kong, 1999 Postdoc, Pharmacology, Yale University, 1999-2002 His research interests span cancer pharmacology, TCM modernization, and mitochondrial toxicity mechanisms. Key projects include YIV-906’s role in enhancing anti-PD1 and CAR T-cell therapies, developing L-nucleoside analogs like troxacitabine, and investigating tylophorine analogs’ antitumor effects. Lam has co-chaired sessions at multiple Consortium for Globalization of Chinese Medicine (CGCM) meetings and contributed to patents on herbal drug formulations and quality control methods. Recent work explores YIV-906’s potential for inflammatory bowel disease (IBD) and phase II clinical trials for colon and liver cancers. Lam’s publications highlight synergistic drug interactions, mitochondrial DNA depletion mechanisms, and TCM’s evidence-based application in chronic diseases. His grants include studies on PHY906 as an adjuvant in rectal cancer therapy and collaborations with Yiviva, Inc. He maintains active roles in editorial boards, including a special issue on herbal drug quality control in Frontiers in Pharmacology . Lam’s lab is embedded within Dr. Yung-Chi Cheng’s group, focusing on translational pharmacology and botanical drug innovation.
Cristian Gómez Canela is a Full Professor in the Department of Analytical and Applied Chemistry at the School of Engineering, Ramon Llull University (IQS). He serves as Coordinator of the Master's Degree in Analytical Chemistry and is an active member of the Catalan Chemical Society (SCQ), representing SCQ in EuChems-EYCN. His academic journey includes a PhD in Chemistry from the University of Barcelona (2014), followed by postdoctoral research at IDAEA-CSIC and King's College University. Dr. Gómez Canela's research focuses on environmental analytical chemistry, particularly the optimization and validation of analytical methods based on liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) and high-resolution mass spectrometry (HRMS) for determining organic pollutants in environmental samples. His work extends to metabolomics applied to aquatic organisms and the analysis of neurotoxic compounds in water systems. His research fingerprint reveals strong expertise in zebrafish models (100%), neurotransmitter analysis (66%), Daphnia magna studies (64%), and neurotoxicity assessment (21%). His recent publications (2024-2025) demonstrate a clear trend toward environmental neurotoxicology, with emphasis on the effects of pharmaceuticals and industrial pollutants on aquatic organisms. His work integrates advanced analytical techniques with biological endpoints to assess environmental risks, particularly focusing on neurological and cardiovascular impacts. The research spans method development for pollutant detection, environmental monitoring, and mechanistic studies of neurotoxic effects. Dr. Gómez Canela leads multiple significant research projects including CHEMIPARK (2024-2027) on passive sampling methodologies for environmental pollutants, GESPA (2022-2025) as part of the Environmental Process Engineering and Simulation Group, and several projects on neuroactive compounds in water systems. He has an impressive research output with 91 scientific publications from 2011-2025 and an h-index of 27 with over 2,000 citations. As a dedicated educator, he contributes to multiple academic programs including the Master in Analytical Chemistry, Master in Pharmaceutical Chemistry, and undergraduate degrees in Chemistry and Chemical Engineering. His research group GESPA represents a multidisciplinary team combining chemical engineering, biotechnology, and chemical analysis to advance environmental sustainability through theoretical and experimental approaches.
Professor Nicholas Buckley is a leading academic in Clinical Pharmacology at the University of Sydney and holds a Visiting Professor position at the University of Peradeniya, Sri Lanka. He serves as Research Director for the South Asian Clinical Toxicology Research Collaboration (SACTRC) and is a Consultant Clinical Pharmacologist & Toxicologist at the NSW Poisons Information Centre and Royal Prince Alfred Hospital. His work focuses on improving clinical toxicology practices, poison control policies, and understanding mechanisms of drug toxicity. Co-founder of SACTRC for agrochemical poisoning and snakebite research Chair of Australian Therapeutic Guidelines - Toxicology writing group Editorial roles in Clinical Toxicology, Drug Safety, and Australian Prescriber Research Interests include toxicovigilance, epidemiology of poisoning, acute kidney injury in poisoning/snakebite, pesticide safety interventions, antidote development, and pharmacoepidemiology of psychotropic drugs. His work combines clinical trials, population surveillance, and translational research. Scientific Contributions span 440+ peer-reviewed articles and 22 book chapters, with continuous funding since 2002. He has supervised over 20 higher degree students and leads international collaborations in low-and-middle-income countries through NIHR RIGHT4. Key Affiliations : Member of Charles Perkins Centre, Australian Medicines Handbook Editorial Advisory Board, and NIHR RIGHT4 programme.
Itsik Pe'er is a Full Professor and Vice-Chair in the Department of Computer Science at Columbia University's Fu Foundation School of Engineering & Applied Science, and holds a joint appointment as Professor of Systems Biology at the Vagelos College of Physicians and Surgeons. His research focuses on computational methods in human genetics, including genetic variation analysis, disease association studies, and algorithm development for genomic data. He leads the Itsik Pe'er Lab of Computational Genomics, which develops tools like Xplorigin, Germline, and SEACells to address challenges in genomics and medical research. His work spans machine learning applications in healthcare, microbiome analysis, and cancer genomics. Notable contributions include studies on hypertensive disorders in pregnancy, bias correction in predictive models, and the development of non-Euclidean learning libraries like Manify. Pe'er has advised students including Vladimir Vacic, Anat Kreimer, and Arthi Ramachandran, and collaborates on grants addressing genetic epidemiology and computational biology. His lab's location is in the Computer Science Building at Columbia's Morningside Campus.
Tim Q. Duong, Ph.D., is a Professor at Albert Einstein College of Medicine, affiliated with the Departments of Radiology, Biochemistry, Ophthalmology & Visual Sciences, and Neuroscience. His research focuses on medical imaging, MRI, image analysis, machine learning, and predictive modeling for studying diseases like COVID-19 , neurodegeneration (Alzheimer's, multiple sclerosis), brain injuries , and breast cancer . Develops AI-driven MRI techniques for early disease detection Investigates neuroplasticity in glaucoma and diabetic retinopathy Leads grants from NIH and National Eye Institute Research Trends : Recent publications emphasize AI integration in medical imaging, long-term effects of SARS-CoV-2, and advanced MRI applications for ocular and neurological disorders. Grants include multiple R01 awards for diabetic retinopathy and glaucoma studies. Training Opportunities : Actively recruits postdocs, research coordinators, and faculty. Offers research positions for graduate, medical, and high school students, including Regeneron Scholar programs. Labs & Teams : Leads the Duong Lab at Montefiore Medical Center, focusing on translational research for clinical imaging solutions.
Professor Matthias Mann is a world-leading scientist serving as Director of the Proteomics and Signal Transduction department at the Max Planck Institute of Biochemistry in Martinsried, Germany, and Director of the Proteomics department at the Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Denmark. With an h-index exceeding 277 and over 350,000 citations, he is recognized as the highest cited German researcher and one of the most influential scientists globally in proteomics. His educational background includes: Ph.D. in Chemical Engineering from Yale University (1988) Master's Degree in Physics from Georg August University Göttingen (1984) Bachelor's of Arts in Mathematics from Georg August University Göttingen (1982) Professor Mann's research focuses on advancing mass spectrometry-based proteomics to understand biological systems at the protein level. His work spans technological developments in mass spectrometry, bioinformatics and computational analysis, signal transduction and posttranslational modifications, and clinical proteomics applications for disease diagnosis and treatment. The Mann lab has pioneered groundbreaking methods like SILAC for quantitative proteomics and MaxQuant for proteome data analysis. Their vision is to translate proteomics knowledge into clinical practice for predictive, diagnostic, and preventive medicine, with recent work focusing on AI-guided platforms for analyzing proteomes from minimal tissue samples. Analysis of Professor Mann's recent publications reveals a strong trend toward clinical applications of proteomics, particularly in cancer research, metabolic diseases, and neurodegenerative disorders. His work increasingly integrates spatial proteomics, single-cell resolution techniques, and artificial intelligence approaches to uncover disease mechanisms and identify potential biomarkers, with a clear shift from basic technology development toward direct clinical applications and personalized medicine. Professor Mann has received numerous prestigious awards throughout his career: 2025: Elected member of the American National Academy of Sciences 2024: Dr. H.P. Heineken Award for Biochemistry and Biophysics 2023: Otto Warburg Medal 2019: Nominated member of the Bavarian Academy of Sciences 2013: Elected member of Leopoldina German National Academy of Sciences 2012: Körber European Science Award, Louis-Jeantet Foundation Prize for Medicine, Ernst Schering Prize, and Leibniz Prize Professor Mann leads a highly collaborative research team involved in multiple international networks including the Bill & Melinda Gates Foundation, Michael J. Fox Foundation for Parkinson's Research, CLINSPECT-M, and Munich Heart Alliance. His lab has mentored numerous successful researchers, with several former postdocs receiving prestigious ERC Starting Grants. The Mann group has developed innovative clinical proteomics pipelines for analyzing archived tissue specimens and body fluids, aiming to identify protein markers for early detection of diseases such as diabetes and cancer. The Mann lab operates across two major research centers with state-of-the-art mass spectrometry facilities. Their Clinical Knowledge Graph platform integrates multi-omics data with extensive metadata, creating an ecosystem for machine learning applications in proteomics. Current research focuses on developing highly sensitive methods that can profile thousands of proteins from minimal cell samples, enabling the identification of critical disease-related proteins and supporting the development of individualized therapies.
Professor Carlo Pappone is a Full Professor of Cardiology at Vita-Salute San Raffaele University (since 2019) and Director of the Arrhythmology Department at IRCCS Policlinico San Donato Hospital (since 2015). He has held previous academic/clinical leadership roles at IRCCS San Raffaele Hospital (2000-2010), Villa Maria Cecilia Hospital (2010-2015), and University of Naples Federico II (1990-2000). With 212 publications in top journals like NEJM, JAMA, and Circulation, he has made significant contributions to cardiac arrhythmia research. Current Positions Vita-Salute San Raffaele University (2019-present): Full Professor of Cardiology IRCCS Policlinico San Donato Hospital (2015-present): Director of Arrhythmology Department Previous Roles University of Naples Federico II (1990-2000) University of Michigan Ann Harbor (1990-2000) IRCCS San Raffaele Hospital (2000-2010) Villa Maria Cecilia Hospital (2010-2015) Research Focus: Specializing in cardiovascular diseases, his work spans atrial fibrillation ablation techniques, Brugada syndrome pathogenesis, heart failure device therapy, and ion channel disorders. His H-index of 53 and 18,407 citations reflect his substantial academic impact. Notable Scientific Contributions Author of 44 patents Principal Investigator in 14 clinical trials (clinicaltrials.gov) Developed circumferential pulmonary vein ablation technique Innovator in biventricular pacing systems for heart failure Pioneered research on non-excitatory current for cardiac contractility Scientific Recognition Awarded as Elite Reviewer of JACC (2005) Editorial Board Member of 6 leading journals Reviewer for NEJM, JAMA, Lancet, and Nature Medicine Education Medical Doctorate: University of Naples Federico II
